Patients with severe community acquired pneumonia admitted to intensive care unit Severe pneumonia, Mortality, Steroids
Conditions
Interventions
Hydrocortisone 200 mg diluted in 100 mL of normal saline, administered intravenously as a loading dose over 30 minutes, followed by Hydrocortisone 240 mg diluted in 500 mL of normal saline, given as a
Active Comparator Drug,Placebo Comparator Drug
Hydrocortisone,Normal saline
Sponsors
Narongdech Butworn
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Severe community acquired pneumonia admitted to intensive care unit, 2. Aged 18 years or older, 3. Admitted to the hospital for no more than 48 hours.
Exclusion criteria
Exclusion criteria: 1. hospital acquired pneumonia, 2. severe immune-deficiency or immunosuppression conditions, 3. severe burn, 4. life expectancy no more than 3 months, 5. pregnancy, 6. admitted with severe gastrointestinal bleeding within 3 months, 7. underlying diseases or conditions requiring corticosteroid treatment at a dose greater than 0.5 mg/kg/day (prednisolone equivalent), 8. influenza virus or coronavirus disease 2019 (COVID-19) infection, 9. receiving hydrocortisone for other indications, such as adrenal insufficiency, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality in hospital Hazard ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality 28 days after treatment Hazard ratio | — |
Countries
Thailand
Contacts
Public ContactNarongdech Butworn
Nakhon Phanom hospital
Outcome results
None listed